We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current CAPS market cap is 504.35k. The company's latest EPS is USD -36.3873 and P/E is -0.09.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 45.45M | 66.74M | 61.56M | 48.35M |
| Operating Income | -762k | 2.4M | 4.64M | 3.99M | -1.26M |
| Net Income | -2.07M | 8.53M | 563k | -10k | -5.74M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 284k | 54.87M | 64.07M | 65.21M | 52.7M |
| Total Liabilities | 4.23M | 25.77M | 34.99M | 31.88M | 23.58M |
| Total Equity | -3.94M | 5.81M | 6.24M | 8.17M | 2.44M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -1.68M | 642k | 3.72M | -2.89M | 1.45M |
| Investing | N/A | -3k | -931k | -173k | -208k |
| Financing | 396k | -697k | -2.74M | 3.04M | -1.21M |
| Market Cap | 504.35k |
| Price to Earnings Ratio | -0.09 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 9.7 |
| Price to Book Ratio | 0.02 |
| Dividend Yield | - |
| Shares Outstanding | 157.61k |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 415 |
| 52 Week Change | -54.29% |
| 52 Week High | 7.00 |
| 52 Week Low | 3.20 |
| Spread (Intraday) | 1 (25%) |
| Company Name | Capstone Therapeutics Corporation (QB) |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.capstonethx.com |
| Industry | surgical,med instr,apparatus (3841) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
